MarketPulse

blood cancer

4 articles
BenzingaBenzinga··Vandana Singh

Pfizer's ELREXFIO Demonstrates Superior Efficacy in Late-Stage Myeloma Trial

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.
PFEPhase 3 trialclinical trial results
BenzingaBenzinga··Vandana Singh

Eli Lilly's Jaypirca Notches Fourth Phase 3 Win, Strengthening Blood Cancer Portfolio

Eli Lilly reports fourth positive Phase 3 trial for Jaypirca in chronic lymphocytic leukemia, positioning drug for label expansion ahead of competitive launches.
JNJABBVLLYPhase 3 trialprogression-free survival
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron to Share Pipeline Progress at Needham Conference as RYTELO® Gains Market Traction

Geron Corporation will discuss its commercial-stage telomerase inhibitor platform at the Needham Healthcare Conference on April 13, highlighting RYTELO® adoption and ongoing Phase 3 trials in myelofibrosis.
GERNclinical trialbiopharmaceutical
BenzingaBenzinga··Vandana Singh

FDA Clears Oral Combination Therapy for Untreated Chronic Lymphocytic Leukemia

FDA approves first all-oral combination therapy for untreated chronic lymphocytic leukemia. The fixed-duration treatment showed 35% reduced progression risk versus chemotherapy.
ABBVRHHBYAZNFDA approvalPhase 3 trial